TMCI vs. SLNO, INMD, CDRE, MDXG, BLFS, RXST, AORT, EMBC, PLSE, and LQDA
Should you be buying Treace Medical Concepts stock or one of its competitors? The main competitors of Treace Medical Concepts include Soleno Therapeutics (SLNO), InMode (INMD), Cadre (CDRE), MiMedx Group (MDXG), BioLife Solutions (BLFS), RxSight (RXST), Artivion (AORT), Embecta (EMBC), Pulse Biosciences (PLSE), and Liquidia (LQDA). These companies are all part of the "medical equipment" industry.
Treace Medical Concepts vs.
Treace Medical Concepts (NASDAQ:TMCI) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
In the previous week, Treace Medical Concepts had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 4 mentions for Treace Medical Concepts and 2 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 1.04 beat Treace Medical Concepts' score of 0.16 indicating that Soleno Therapeutics is being referred to more favorably in the news media.
84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 24.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 12.3% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Treace Medical Concepts has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.47, meaning that its stock price is 247% less volatile than the S&P 500.
Treace Medical Concepts presently has a consensus price target of $8.98, indicating a potential upside of 3.14%. Soleno Therapeutics has a consensus price target of $74.83, indicating a potential upside of 59.63%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Treace Medical Concepts.
Soleno Therapeutics has lower revenue, but higher earnings than Treace Medical Concepts. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics received 285 more outperform votes than Treace Medical Concepts when rated by MarketBeat users. Likewise, 72.09% of users gave Soleno Therapeutics an outperform vote while only 46.30% of users gave Treace Medical Concepts an outperform vote.
Soleno Therapeutics has a net margin of 0.00% compared to Treace Medical Concepts' net margin of -30.33%. Treace Medical Concepts' return on equity of -51.12% beat Soleno Therapeutics' return on equity.
Summary
Soleno Therapeutics beats Treace Medical Concepts on 10 of the 18 factors compared between the two stocks.
Get Treace Medical Concepts News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Treace Medical Concepts Competitors List
Related Companies and Tools
This page (NASDAQ:TMCI) was last updated on 1/21/2025 by MarketBeat.com Staff
Free TMCI Stock Alerts